Salestools LogoSalestools
Agenti IA Salestools
Soluzioni
Risorse
Azienda
Prezzi
Salestools Logo

Salestools

L'agente IA #1 per team di vendita e Go-to-Market. Vendi di più, più velocemente, con meno sforzo.

Prodotto

  • Agenti di vendita IA
  • Dati di intenzione
  • Dati Tecnologici
  • Tracciamento Visitatori
  • Co-Pilota
  • Vendita Sociale

Soluzioni

  • Servizio Clienti
  • E-commerce
  • SaaS
  • Impresa
  • Piccole Imprese

Risorse

  • Il rapporto
  • Documentazione
  • Riferimento API
  • Centro assistenza
  • Blog
  • Casi studio
  • Webinar

Azienda

  • Chi siamo
  • Carriere
  • Stampa
  • Contatto
  • Partner

Le nostre sedi

  • New York, HQ
  • Bucarest, Laboratorio di Ricerca IA
  • Zug, Svizzera

© 2026 Salestools. Tutti i diritti riservati.

Termini sui Dati e SicurezzaPolitica sulla privacyTermini di servizioAcceptable Use
Tutti i sistemi operativi
Salestools LogoSalestools
Agenti IA Salestools
Soluzioni
Risorse
Azienda
Prezzi
Back to Reports
Fundraising

Gilead Sciences

Gilead Sciences Raises $100B in Public

333 Lakeside Drive, Foster City, CA 94404January 1, 20242 min read
Employees
17000+

Gilead Sciences Raises $100B in Public


Gilead Sciences has successfully raised $100B in a Public at a $110B valuation led by Public.


Company Overview


Gilead Sciences is a Biotech company headquartered in 333 Lakeside Drive, Foster City, CA 94404, founded in 1987 with 17000+ employees.


Biopharmaceutical company


Fundraising Details


  • Amount Raised: $100B
  • Round Type: Public
  • Valuation: $110B
  • Date: 2024-01-01
  • Investors: Public

About Gilead Sciences


Biopharmaceutical company The company is positioned in the Biotech sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: 333 Lakeside Drive, Foster City, CA 94404
  • Founded: 1987
  • Team Size: 17000+
  • Industry: Biotech

What This Means


This funding round demonstrates strong investor confidence in Gilead Sciences's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The Biotech sector continues to attract significant investment as companies innovate to meet evolving market demands. Gilead Sciences's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $110B valuation marks an important milestone for Gilead Sciences, positioning the company among notable players in the Biotech industry.


Looking Ahead


With this new capital, Gilead Sciences is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2024-01-01. For more information about Gilead Sciences, visit their headquarters at 333 Lakeside Drive, Foster City, CA 94404.

Company Info

Headquarters
333 Lakeside Drive, Foster City, CA 94404
Founded
1987
Team Size
17000+

Topics

Fundraising(2912)Public(771)BiotechGilead Sciences

Share

Related Reports

Fundraising
Tebra

Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform

Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.

SalesTools Research
SalesTools Research
Jan 12, 2026
0 min read•$250M
Fundraising
Harmattan AI

Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation

French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M
Fundraising
AirNexis Therapeutics

AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment

Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free